Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 4 1Phase 3 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 8Gastrointestinal 6Thoracic 5CNS 4Other hematologic neoplasm 3Dermatologic 3Head & Neck 2Genitourinary 2Myeloid 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 1Chemotherapy-Related Cognitive Impairment 1Breast Neoplasms 1

Interventions

Rituximab 689Cyclophosphamide 615Vincristine 285Etoposide 272Doxorubicin 271Cytarabine 230Prednisone 229Methotrexate 221fludarabine phosphate 189Filgrastim 187Dexamethasone 180fludarabine 176Lenalidomide 165Radiotherapy 128Melphalan 127Peripheral Blood Stem Cell Transplantation 123Busulfan 118Bendamustine Hydrochloride 116Granulocyte Colony-Stimulating Factor 113Bortezomib 112ibrutinib 111Mycophenolic Acid 110venetoclax 106Whole-Body Irradiation 106obinutuzumab 105Tacrolimus 105Gemcitabine 92zanubrutinib 81Specimen Handling 80Cyclosporine 76

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sodium Chloride × Lymphoid × Clear all
NCT01205503 2016-02-24

Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release

University of Kentucky

Phase 2 Completed
32 enrolled 24 charts
BreastLymphoid

Chemotherapy-Related Cognitive Impairment, Breast Neoplasms, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡